Your browser doesn't support javascript.
loading
Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
Montalban, Gemma; Fraile-Bethencourt, Eugenia; López-Perolio, Irene; Pérez-Segura, Pedro; Infante, Mar; Durán, Mercedes; Alonso-Cerezo, María Concepción; López-Fernández, Adrià; Diez, Orland; de la Hoya, Miguel; Velasco, Eladio A; Gutiérrez-Enríquez, Sara.
Affiliation
  • Montalban G; Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fraile-Bethencourt E; Splicing and genetic susceptibility to cancer, Instituto de Biología y Genética Molecular (CSIC-UVa), Valladolid, Spain.
  • López-Perolio I; Molecular Oncology Laboratory CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
  • Pérez-Segura P; Molecular Oncology Laboratory CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
  • Infante M; Cancer Genetics, Instituto de Biología y Genética Molecular (CSIC-UVa), Valladolid, Spain.
  • Durán M; Cancer Genetics, Instituto de Biología y Genética Molecular (CSIC-UVa), Valladolid, Spain.
  • Alonso-Cerezo MC; Genética Clínica. Servicio Análisis Clínicos. Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, Madrid, Spain.
  • López-Fernández A; High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Diez O; Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • de la Hoya M; Area of Clinical and Molecular Genetics, University Hospital of Vall d'Hebron, Barcelona, Spain.
  • Velasco EA; Molecular Oncology Laboratory CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
  • Gutiérrez-Enríquez S; Splicing and genetic susceptibility to cancer, Instituto de Biología y Genética Molecular (CSIC-UVa), Valladolid, Spain.
Hum Mutat ; 39(9): 1155-1160, 2018 09.
Article in En | MEDLINE | ID: mdl-29969168
ABSTRACT
Many BRCA1 and BRCA2 (BRCA1/2) genetic variants have been studied at mRNA level and linked to hereditary breast and ovarian cancer due to splicing alteration. In silico tools are reliable when assessing variants located in consensus splice sites, but we may identify variants in complex genomic contexts for which bioinformatics is not precise enough. In this study, we characterize BRCA2 c.7976 + 5G > T variant located in intron 17 which has an atypical donor site (GC). This variant was identified in three unrelated Spanish families and we have detected exon 17 skipping as the predominant transcript occurring in carriers. We have also detected several isoforms (Δ16-18, Δ17,18, Δ18, and ▼17q224 ) at different expression levels among carriers and controls. This study remarks the challenge of interpreting genetic variants when multiple alternative isoforms are present, and that caution must be taken when using in silico tools to identify potential spliceogenic variants located in GC-AG introns.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alternative Splicing / BRCA2 Protein / Hereditary Breast and Ovarian Cancer Syndrome / Mutation Type of study: Prognostic_studies Limits: Aged / Aged80 / Female / Humans Language: En Journal: Hum Mutat Journal subject: GENETICA MEDICA Year: 2018 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alternative Splicing / BRCA2 Protein / Hereditary Breast and Ovarian Cancer Syndrome / Mutation Type of study: Prognostic_studies Limits: Aged / Aged80 / Female / Humans Language: En Journal: Hum Mutat Journal subject: GENETICA MEDICA Year: 2018 Type: Article Affiliation country: Spain